Compositions and methods for prophylaxis and treatment of addictions
View Patent ↗The present invention relates to methods of treating or preventing addiction and relapse use of addictive agents, and treating or preventing addictive or compulsive behavior and relapse practice of an addictive behavior or compulsion, by administering a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, alone or in combination with another therapeutic agent, such as, for example, an opioid receptor antagonist or an antidepressant, or an addictive agent, such as, for example, an opioid agonist. The present invention also includes pharmaceutical compositions for treating or preventing addiction or relapse that include a PPARγ agonist and one or more other therapeutic or addictive agents, as well as unit dosage forms of such pharmaceutical compositions, which contain a dosage effective in treating or preventing addiction or relapse. The methods and compositions of the invention are useful in the treatment or prevention of addiction to any agent, including alcohol, nicotine, marijuana, cocaine, and amphetamines, as well as compulsive and addictive behaviors, including pathological gambling and pathological overeating.
1. A method of treating or reducing the likelihood of an addiction, comprising:
determining that a subject has an addiction to an addictive agent or to the practice of an addictive or compulsive behavior;
determining that the subject has (a) undergone a period of abstinence from or limited or reduced use of the addictive agent, or (b) undergone a period of abstinence from or limited or reduced practice of the addictive or compulsive behavior; and
providing to the subject an amount of an agonist of a peroxisome proliferator-activated receptor gamma (PPARγ agonist) effective to reduce the reward action from practice of the addiction, wherein the PPARγ agonist is a thiazolidinedione (TZD) and wherein the PPARγ agonist is effecting for treating or preventing relapse use of the addictive agent or practice of the addictive or compulsive behavior.
2. The method of claim 1 , wherein the subject is addicted to an addictive agent.
3. The method of claim 2 , wherein the subject is addicted to an addictive agent selected from the group consisting of: alcohol, nicotine, marijuana, a marijuana derivative, an opioid agonist, a benzodiazepine, a barbiturate, and a psychostimulant.
4. The method of claim 3 , wherein the addictive agent is nicotine.
5. The method of claim 3 , wherein the addictive agent is an opioid agonist is selected from the group consisting of: morphine, methadone, fentanyl, sufentanil, and diacetylmorphine (heroin), alfentanil, allylprodine, alphaprodine, anileridine, apomorphine, benzylmorphine, beta-hydroxy 3-methylfentanyl, bezitramide, carfentanil, clonitazene, codeine, desomorphine, dextromoramide, diampromide, dihydrocodeine, dihydroetorphine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetylbutyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, etorphine, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, LMM, levorphanol, levophenacylmorphan, lofentanil, meperidine, metopon, metazocine, methadyl acetate, metapon, myrophine, narceine, nicomorphine, norlevorphanol, normethadone, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaverine, phenadoxone, phenomorphan, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propoxyphene, remifentanil, thebaine, tildine, tramadol, noscapine, nalorphine, naloxone, naltrexone, phenazocine and propoxyphene.
6. The method of claim 3 , wherein the addictive agent is a psychostimulant selected from the group consisting of cocaine, amphetamine or and an amphetamine derivative.
7. The method of claim 1 , wherein the subject is addicted to an addictive or compulsive behavior.
8. The method of claim 7 , wherein the addictive or compulsive behavior is selected from the group consisting of: pathological gambling, pathological overeating, pathological use of electronic devices, pathological use of electronic video games, pathological use of electronic communication devices, pathological use of cellular telephones, addiction to pornography, sex addiction, obsessive compulsive disorder, compulsive spending, anorexia, bulimia, intermittent explosive disorder, kleptomania, pyromania, trichotillomania, compulsive overexercising, and compulsive overworking.
9. The method of claim 1 , wherein the TZD is selected from the group consisting of: pioglitazone, rosiglitazone, ciglitazone, troglitazone, englitazone, rivoglitazone and darglidazone.
10. The method of claim 9 , wherein the TZD is pioglitazone.
11. The method of claim 1 , further comprising providing an additional therapeutic agent, wherein each of the PPARγ agonist and the additional therapeutic agent contribute to the effective treatment or prevention of the addiction.
12. The method of claim 11 , wherein said additional therapeutic agent is selected from the group consisting of: an opioid antagonist, a mixed opioid partial agonist/antagonist, an antidepressant, an antiepileptic, an antiemetic, a corticotrophin-releasing factor-1 (CRF-1) receptor antagonist, a selective serotonin-3 (5-HT3) antagonist, a 5-HT2A/2C antagonist, and a cannabinoid-1 (CB1) receptor antagonist.
13. The method of claim 11 , wherein the additional therapeutic agent is an opioid antagonist selected from the group consisting of naltrexone and nalmefene.
14. The method of claim 11 , wherein the additional therapeutic agent is an antidepressant selected from the group consisting of fluoxetine, mirtazapine, and bupropion.
15. The method of claim 11 , wherein the additional therapeutic agent is an antiepileptic selected from the group consisting of benzodiazepines, barbituates, valproates, GABA agents, iminostilibenes, hydantoins, NMDA antagonists, sodium channel blockers and succinamides.
16. The method of claim 11 , wherein the additional therapeutic agent is a CRF-1 receptor antagonist that is antalarmin.
17. The method of claim 11 , wherein the additional therapeutic agent is a selective serotonin-3 (5-HT3) antagonist that is ondansetron.
18. The method of claim 11 , wherein the additional therapeutic agent is a cannabinoid-1 (CB1) receptor antagonist selected from the group consisting of rimonabant and tanarabant.
19. The method of claim 11 , wherein the additional therapeutic agent is a mixed opioid agonist/antagonist that is buprenorphine.
20. The method of claim 1 , wherein the subject previously reduced or eliminated use of the addictive agent or practice of the addictive or compulsive behaviour in response to treatment with an effective amount of an anti-addiction treatment, and wherein the subject is no longer exposed to an effective amount of the anti-addiction treatment.